This suggest that the treatments of G1 and PCA can effectively down-regulate the inflammatory markers (VCAM-1 and CD40) and up-regulate GPER-1 and CD31 to attenuate atherosclerosis for both short and long term. Here, GPER1 is linked to atherosclerosis.